Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679492 | 0.84 | TSHR (0.50) | ALDH1A1HPGDNPC1L3MBTL1POLB | |
| SCHEMBL2153551 | 0.82 | CES2 (0.62) | CES2CES1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL36252 | 0.82 | CES2 (0.62) | CES2CES1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL17787536 | 0.80 | KAT6A (0.43) | CES2CES1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL29508856 | 0.80 | CES2 (0.60) | CES2CES1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1171 | 0.80 | CES2 (0.60) | CES2CES1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13302406 | 0.80 | CES2 (0.60) | CES2CES1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL27947848 | 0.80 | FABP4 (0.51) | CES2CES1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL196555 | 0.78 | LMNA (0.61) | CES2CES1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL515569 | 0.78 | CES2 (0.58) | CES2CES1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | NIPPON CHEMIPHAR CO., LTD. | 2007-11-15 | — | — | US | disclosed |
| US-7253154-B2 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | GENENTECH, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050090472-A1 | Xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| CN-1191063-C | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1114046-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2001-07-11 | — | — | EP | disclosed |
| CN-1295471-A | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2001-05-16 | — | — | CN | disclosed |
| WO-2000017195-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0804440-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0804420-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | VCAM1, CD58, ITGB8 | CES2 3028/4885CES1 2074/4885ALDH1A1 280/4885 |
| US-20050090472-A1 | Xanthine oxidase inhibitors | XDH, CBR1, NOX1 | CES2 176/4885CES1 87/4885ALDH1A1 706/4885 |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | XDH, CBR1, NOX1 | CES2 177/4885CES1 86/4885ALDH1A1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.